These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27792008)

  • 21. The economics of adalimumab for ulcerative colitis.
    Xie F
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humira: the first $20 billion drug.
    Gibbons JB; Laber M; Bennett CL
    Am J Manag Care; 2023 Feb; 29(2):78-80. PubMed ID: 36811981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
    Mengato D; Messori A
    Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
    [No Abstract]   [Full Text] [Related]  

  • 25. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Online Prescription Management Systems on Biologic Treatment Initiation.
    Hawkes JE; Mittal M; Davis M; Brixner D
    Adv Ther; 2019 Aug; 36(8):2021-2033. PubMed ID: 31168763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Older anti-TNF-α agents: why not group them for common indications in the EU?
    Garattini L; Ghislandi F; Padula A
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):1-4. PubMed ID: 26751100
    [No Abstract]   [Full Text] [Related]  

  • 30. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
    Chen BK; Yang YT; Bennett CL
    Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab and the Challenges for Biosimilars.
    Gellad WF; Good CB
    JAMA; 2019 Dec; 322(22):2171-2172. PubMed ID: 31644784
    [No Abstract]   [Full Text] [Related]  

  • 33. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of anti-tumor necrosis factor agents.
    Wong JB
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S65-70. PubMed ID: 15552517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
    Coghlan J; He H; Schwendeman AS
    J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategic considerations under the Biologics Price Competition and Innovation Act.
    Marquardt JL; Auten SR
    Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.